ArticleBMJ open2022

Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial-a study protocol of clinical trial.

Ruyuan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.